The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 7, 2019. Its latest SEC filing is a 3 from Oct 31, 2022.
10-Q for Q3 FY2019, filed Nov 7, 2019
The sections below describe the company as of the FY2018 annual report.
Develops gene therapy products for patients with serious rare diseases caused by single-gene defects, including rare neuromuscular diseases.
10-K for FY2018, filed Mar 1, 2019
No revenue was reported.
10-K for FY2018, filed Mar 1, 2019
Develops therapies for patients with rare diseases.
10-K for FY2018, filed Mar 1, 2019We are a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with…View ↗
10-Q for Q3 FY2019, filed Nov 8, 2019
−$45.7MView ↗
8-K, filed Jan 15, 2020
Also on January 15, 2020, following acceptance of the tendered Shares and pursuant to the terms of the Merger Agreement and in accordance…View ↗
Competes with Valerion Therapeutics, IONIS Pharmaceuticals, Dynacure, Genzyme, Amicus Therapeutics, Oxyrane, Spark Therapeutics, AVROBIO, Lacerta Therapeutics, Regeneron Pharmaceuticals, Actus Therapeutics, Genethon, Selecta Biosciences, LogicBio Therapeutics, and Promethera
10-K for FY2018, filed Mar 1, 2019For the treatment of XLMTM, Valerion Therapeutics, LLC, or Valerion, is studying VAL-0620, a fusion protein consisting of an antibody…View ↗
Loading...
